Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

[O]ral semaglutide 14 mg (or flexible dosing, in PIONEER 7) was generally more effective at improving multiple cardiometabolic risk factors — including HbA 1c, [body weight], SBP, and LDL ...

Single dose of Vivani’s NPM-139 semaglutide implant led to nearly 20% weight loss in rats, suggesting once- or twice-yearly dosing. NPM-139 showed steady semaglutide release with potential for ...

ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical ...

52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1 ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development ... administration with expected once or twice-yearly ...

Lexaria Bioscience (LEXX) announced that dosing has begun as scheduled in ... as well as reduced adverse events as compared to the oral semaglutide and injectable tirzepatide products on the ...

The American drugmaker will roll out tirzepatide, sold under the brand name Mounjaro, in single-dose vials after receiving ... it contains the same ingredient semaglutide as Wegovy and Ozempic ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM ... its subdermal semaglutide implant under ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature ... its subdermal semaglutide ...